Table 1 Clinical and histological characteristics of M0CRPC patients.
Patients, n | 82 |
Age at PC diagnosis, years | 71 (54–89) |
Age at CRPC diagnosis, years | 76 (55–94) |
PSA at PC diagnosis, ng/mL | 25.8 (3.82–534) |
PSA at CRPC diagnosis, ng/mL | 2.84 (2.04–22.5) |
Clinical stage | |
Tx | 12 (14.6) |
T1-T2 | 32 (39.0) |
T3 | 31 (37.8) |
T4 | 7 (8.5) |
N0 | 71 (86.6) |
N1 | 11 (13.4) |
Gleason scorea, n | |
6 | 4 (4.8) |
7 | 22 (26.8) |
8 | 17 (20.7) |
≥ 9 | 39 (47.6) |
Localized treatment | |
None | 44 (53.7) |
Radical prostatectomy | 15 (18.3) |
External beam radiation | 17 (20.7) |
Brachytherapy | 6 (7.3) |
Type of ADT | |
Surgical orchiectomy | 5 (6.1) |
Luteinizing hormone-releasing hormone agonist | 76 (92.7) |
Luteinizing hormone-releasing hormone antagonist | 1 (1.1) |
Nadir PSA under ADT treatment, ng/mL | 0.18 (0.00–14.7) |
PSA reduction rate, % | 99.4 (71.3–100) |
TnPSA from the start of ADT, months | 15 (1–126) |
TTCRPC, months | 53 (1–190) |
PSADT, months | 3.6 (0.8–32.4) |
First-line treatment for CRPC | |
Docetaxel | 23 (28.0) |
Abiraterone acetate | 6 (7.3) |
Enzalutamide | 21 (25.6) |
Other therapies | |
Flutamide | 19 (23.2) |
Low-dose dexamethasone | 9 (11.0) |
Estramustine | 4 (4.9) |
Cycles of docetaxel treatment | 6 (2–23) |
